Alcon Inc. Announces Major Acquisition

In a significant development in the eye care industry, Alcon Inc. revealed on Tuesday its definitive agreement to acquire STAAR Surgical Company for a staggering $1.5 billion.

Expanding Vision Correction Solutions

The Swiss-American giant highlighted that this merger includes the innovative EVO vision correction lenses, designed specifically for patients suffering from moderate to high myopia. Under the terms of the agreement, Alcon is set to purchase all shares of STAAR common stock at $28 per share, with the transaction anticipated to close within the next six to 12 months.

CEO's Vision for the Future

"With the global rise in high myopia cases, acquiring STAAR empowers us to deliver superior surgical vision correction options for individuals unsuitable for other refractive surgeries like LASIK," stated Alcon CEO David Endicott. "This acquisition enables us to offer a comprehensive range of treatment options for myopia, from contact lenses to surgical solutions, underscoring our dedication to meeting the critical needs in eye care."